Literature DB >> 14767999

The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure.

Nicholas Murphy1, Georg Auzinger, William Bernel, Julia Wendon.   

Abstract

Acute liver failure (ALF) is a rare condition characterized by the development of encephalopathy in the absence of chronic liver disease. Cerebral edema occurs in up to 80% of patients with Grade IV encephalopathy. In the current prospective randomized controlled clinical trial, we examined the effect of induced hypernatremia on the incidence of intracranial hypertension (IH) in patients with ALF. Thirty patients with ALF and Grade III or IV encephalopathy were randomized. Patients in Group 1 (n = 15) received the normal standard of care. Patients in Group 2 (n = 15) received standard care and hypertonic saline (30%) via infusion to maintain serum sodium levels of 145-155 mmol/L. Intracranial pressure (ICP) was monitored in all patients with a subdural catheter (Camino Systems, San Diego, CA) for up to 72 hours after inclusion. Serum sodium levels became significantly different from the levels observed in the control group at 6 hours (P <.01). Over the first 24 hours, norepinephrine dose increased relative to baseline in the control group (P <.001; 13 patients) but not in the treatment group. ICP decreased significantly relative to baseline over the first 24 hours in the treatment group (P =.003; 13 patients) but not in the control group. The incidence of IH, defined as a sustained increase in ICP to a level of 25 mm Hg or greater, was significantly higher in the control group (P =.04). In conclusion, induction and maintenance of hypernatremia can reduce the incidence and severity of IH in patients presenting with ALF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767999     DOI: 10.1002/hep.20056

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  68 in total

1.  The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure.

Authors:  Wai Kwan Lai; Geoff Haydon; David Mutimer; Nick Murphy
Journal:  Intensive Care Med       Date:  2005-09-10       Impact factor: 17.440

2.  Brain preservation during orthotopic liver transplantation in a patient with acute liver failure and severe elevation of intracranial pressure.

Authors:  Alexandru Gottlieb; Kathrine R DeBoer
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

Review 3.  Brain edema in acute liver failure: can it be prevented? Can it be treated?

Authors:  Andres T Blei
Journal:  J Hepatol       Date:  2007-02-05       Impact factor: 25.083

Review 4.  Acute liver failure.

Authors:  J G O'Grady
Journal:  Postgrad Med J       Date:  2005-03       Impact factor: 2.401

Review 5.  Osmotherapy in neurocritical care.

Authors:  Anish Bhardwaj
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

6.  Use of High-Flow Continuous Renal Replacement Therapy with Citrate Anticoagulation to Control Intracranial Pressure by Maintaining Hypernatremia in a Patient with Acute Brain Injury and Renal Failure.

Authors:  Joshua E Medow; Shalin R Sanghvi; R Michael Hofmann
Journal:  Clin Med Res       Date:  2014-12-08

7.  Acute liver failure.

Authors:  Mohammed A Arshad; Nicholas Murphy; Mansoor N Bangash
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

Review 8.  Acute Fatty Liver of Pregnancy: Pathophysiology, Anesthetic Implications, and Obstetrical Management.

Authors:  Emily E Naoum; Lisa R Leffert; Hovig V Chitilian; Kathryn J Gray; Brian T Bateman
Journal:  Anesthesiology       Date:  2019-03       Impact factor: 7.892

Review 9.  Therapeutic hypothermia for acute liver failure: toward a randomized, controlled trial in patients with advanced hepatic encephalopathy.

Authors:  R Todd Stravitz; William M Lee; Andreas H Kramer; David J Kramer; Linda Hynan; Andres T Blei
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

10.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.